News
ZVRA
9.40
-0.11%
-0.01
Zevra Therapeutics Earnings Call Signals Profitable Turn
TipRanks · 3d ago
Weekly Report: what happened at ZVRA last week (0323-0327)?
Weekly Report · 6d ago
Weekly Report: what happened at ZVRA last week (0316-0320)?
Weekly Report · 03/23 09:39
Assessing Zevra Therapeutics (ZVRA) Valuation After Recent Share Price Moves And Rare Disease Milestone
Simply Wall St · 03/21 13:09
Zevra Therapeutics grants CFO Justin Renz 300,000-share option at USD 9.55 exercise price
Reuters · 03/20 20:30
ZEVRA THERAPEUTICS REPORTS INDUCEMENT GRANT TO NEW CHIEF FINANCIAL OFFICER UNDER NASDAQ LISTING RULE 5635(C)(4)
Reuters · 03/20 20:30
Zevra Therapeutics CFO Justin A. Renz Files Initial Beneficial Ownership Statement
Reuters · 03/19 20:15
Zevra Pharmaceuticals: SDX Monetization, Debt Elimination, and Miplyffa Ramp Support Buy Rating
TipRanks · 03/16 22:05
3 Best Stocks to Buy Today, 3/16/2026, According to Top Analysts
TipRanks · 03/16 15:50
Zevra Shares Jump After Selling SDX Portfolio For $50M
Benzinga · 03/16 13:26
This Qualcomm Analyst Turns Bearish; Here Are Top 5 Downgrades For Monday
Benzinga · 03/16 12:57
Zevra Sells SDX Portfolio and Resolves Litigation
TipRanks · 03/16 12:02
Zevra Therapeutics Agrees To Sell Its Serdexmethylphenidate Portfolio, Including AZSTARYS And KP1077, To Commave Therapeutics For $50M
Benzinga · 03/16 11:39
This Cohu Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday
Benzinga · 03/16 11:37
Zevra Therapeutics sells SDX portfolio to Commave for $50M
TipRanks · 03/16 11:35
ZEVRA THERAPEUTICS SELLS SDX PORTFOLIO TO COMMAVE THERAPEUTICS FOR $50 MILLION
Reuters · 03/16 11:30
Zevra Therapeutics Price Target Announced at $23.00/Share by BTIG
Dow Jones · 03/16 10:55
BTIG Initiates Coverage On Zevra Therapeutics with Buy Rating, Announces Price Target of $23
Benzinga · 03/16 10:45
Zevra Therapeutics initiated with a Buy at BTIG
TipRanks · 03/16 10:41
Weekly Report: what happened at ZVRA last week (0309-0313)?
Weekly Report · 03/16 09:38
More
Webull provides a variety of real-time ZVRA stock news. You can receive the latest news about Zevra Therapeutics Inc through multiple platforms. This information may help you make smarter investment decisions.
About ZVRA
Zevra Therapeutics, Inc. is a commercial-stage rare disease company combining science, data, and patient need to create transformational therapies for diseases with limited or no treatment options. It has a diverse portfolio of products and product candidates, which includes pre-clinical, clinical, and commercial stage assets. Its active commercial products and development assets include MIPLYFFA, OLPRUVA, Celiprolol, KP1077IH, KP1077N and AZSTARYS. MIPLYFFA (arimoclomol) is its approved therapy for the treatment of Niemann-Pick disease type C (NPC). OLPRUVA (sodium phenylbutyrate) is its treatment for the treatment of certain urea cycle disorders (UCDs). Celiprolol is its investigational clinical candidate for the treatment of Vascular Ehlers-Danlos Syndrome (VEDS). KP1077 is its product candidate intended for the treatment of rare sleep disorders. KP1077N is a clinical development candidate for narcolepsy. AZSTARYS is for the treatment of attention deficit and hyperactivity disorder.